Jaguar8 commented on a stock · Sep 9, 2024 19:34

NEWS

Botensilimab/Balstilimab Clinical Activity in Refractory Sarcomas to be Presented in Oral Session at ESMO 2024

Agenus Inc. (Nasdaq: AGEN) announced that updated data from the clinical trial of botensilimab and balstilimab in refractory sarcomas will be presented at the ESMO Congress 2024 in Barcelona. The presentation will showcase updated efficacy and safety data from the ongoing Phase 1 trial, highlighting the potential of this combination therapy in treating patients with refractory sarcomas, including visceral angiosarcoma and leiomyosarcoma.
Botensilimab, a novel Fc-enhanced CTLA-4 inhibitor, and balstilimab, a PD-1 antibody, have shown promising clinical responses in multiple tumor types, including 'cold' tumors typically unresponsive to standard therapies. The presentation, titled 'Updated efficacy and safety of botensilimab plus balstilimab in patients with refractory metastatic sarcoma from an expanded phase 1 study,' will be given by Dr. Breelyn A. Wilky on September 13th, 2024.

Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only. Read more

Translate

Report

8193 Views

Comment

Jaguar8

Spread kindness and love. Life is short. Don’t let greed eat you.

6452

Followers

Following

69K

Visitors